key: cord-0733191-c3gro4uh
authors: Steinberg, Jecca R.; Weeks, Brannon T.; Reyes, Griselda A.; Conway Fitzgerald, Alison; Zhang, Wendy Y.; Lindsay, Sarah E.; Anderson, Jill N.; Chan, Katelyn; Richardson, Michael T.; Magnani, Christopher J.; Igbinosa, Irogue; Girsen, Anna; El-Sayed, Yasser Y.; Turner, Brandon E.; Lyell, Deirdre J.
title: The obstetric research landscape: a cross-sectional analysis of clinical trials from 2007-2020
date: 2020-10-06
journal: Am J Obstet Gynecol MFM
DOI: 10.1016/j.ajogmf.2020.100253
sha: 49db22a18c234374a1c488e96f15ee57133a0c0c
doc_id: 733191
cord_uid: c3gro4uh

Background Obstetric complications impact over a third of women globally, but are underrepresented in clinical research. Little is known about the comprehensive obstetric clinical trial landscape, how it compares to other fields, or factors associated with the successful completion of obstetric trials. Objectives To characterize obstetric clinical trials registered on ClinicalTrials.gov with the primary objective of identifying features associated with early discontinuation and results reporting. Study Design This is a cross-sectional study with descriptive, logistic regression and cox regression analyses of clinical trials registered on ClinicalTrials.gov. Our primary exposure variables were trial focus (obstetric or non-obstetric) and trial funding (industry, United States government or academic). We conducted additional exploratory analyses of other trial features including design, enrollment, and therapeutic focus. We examined the associations of exposure variables and other trial features with two primary outcomes: early discontinuation and results reporting. Results We downloaded data for all studies (n=332,417) registered on ClinicalTrials.gov from October 1, 2007 to March 9, 2020 from the Aggregate Analysis of the ClinicalTrials.gov database. We excluded studies with a non-interventional design (n=63,697) and those registered before October 1, 2007 (n=45,209). 4,276 (1.9%) obstetric trials (i.e. interventional studies), and 219,235 (98.1%) non-obstetric trials were compared. Among all trials, 2.8% of academic-funded trials, 1.9% of United States government-funded trials, and 0.4% of industry-funded trials focused on obstetrics. The quantity of obstetric trials increased over time (10.8% annual growth rate). Compared to non-obstetric trials, obstetric trials had a greater risk of early discontinuation (adjusted hazard ratio 1.40, 95% confidence interval: 1.21 to 1.62, p<0.0001) and similar odds of results reporting (adjusted odds ratio 0.89, 95% confidence interval: 0.72 to 1.10, p=0.19). Among obstetric trials funders after controlling for confounding variables, United States government-funded trials were at lowest risk of early discontinuation (US government adjusted hazard ratio 0.23, 95% confidence interval 0.07 to 0.69, p=0.009, industry reference; academic adjusted hazard ratio 1.04, 95% confidence interval 0.62 to 1.74, p=0.88). Academic-funded trials had the lowest odds of results reporting after controlling for confounding variables (academic institutions adjusted odds ratio 0.39, 95% confidence interval 0.22 to 0.68, p=0.0009; industry reference; US government adjusted odds ratio 1.06 95% confidence interval 0.53 to 2.09, p=0.87). Conclusions Obstetric trials represent only 1.9% of all clinical trials in ClinicalTrials.gov and have comparatively poor completion. All stakeholders should commit to increasing the number of obstetric trials and improving their completion and dissemination to ensure clinical research reflects the obstetric burden of disease and advances maternal health.

For analysis each therapeutic focus was treated as a binary variable with two categories: 138

(1) Trials labeled with the therapeutic focus; (2) All other trials that were not labeled with the 139 therapeutic focus. 140 141

Our primary exposure variables were trial focus (obstetric or non-obstetric) and trial funding 143 (industry, United States (US) government or academic). We conducted additional exploratory 144 analyses of other trial features including characteristics, design, enrollment, and therapeutic 145 focus. Obstetric trials were compared to non-obstetric trials in terms of funding source and other 146 trial features. Obstetric trial features were compared by trial funder as well. 147 primary outcomes: early discontinuation and results reporting within three years of trial 149 completion. "Early discontinuation" was defined as a trial stopped early with the status 150 "Terminated," or "Suspended." In analysis of early discontinuation, we excluded trials 151 documented as having less than one day duration (2.1%), trials with the status "Withdrawn" 152 (defined as those terminating prior to the enrollment of participants, 2.8%), and trials without a 153 verified status (13.2%). 19 We summarized data with descriptive statistics including frequencies, percentages and two-sided 179

Pearson chi-square tests. We analyzed change over time, independence and significance with 180 annual growth rates and post-hoc Mann-Kendall tests respectively. 24 Only years with a 181 The funding sources of obstetric trials differed from non-obstetric trials, with the vast majority of 213 obstetric clinical trials funded by academic institutions (85.5%) followed by the US government 214 (7.7%) and industry (6.8%; Figure 2 , Table S1 ). In contrast, a large proportion of non-obstetric 215 proportion funded by the US government (7.9%). Among all trials, obstetrics was the focus in 217 2.8% of academic-funded trials, 1.9% of US government-funded trials, and 0.4% of industry-218 funded trials. 219 220

Obstetric trials focused on prevention more frequently (31.5%, vs. 10.2%) and on treatment less 222 frequently than non-obstetric trials (39.3% vs. 64.0%, Table S1 ). Obstetric trials had more 223 participants per trial (enrollment >100: 61.5% vs. 35.4%), and had more frequent blinding, 224 randomization, and reporting to a Data Safety Monitoring Committee. A greater proportion of 225 obstetric trials occurred exclusively in low and middle-income countries (27.5%) compared to 226 non-obstetric trials (13.9%). The quantity of obstetric trials increased at a greater annual growth 227 rate than non-obstetric trials (obstetric 10.8% vs. non-obstetric 4.8%; Table S2 ). 228 229

Funding 231

Within obstetric trials, compared with other sources of funding, those with US government-232 funding had more randomization, increased enrollment (>100), and more oversight by a Data 233 Safety Monitoring Committee (Table 1 ). In contrast, a greater proportion of obstetric trials with 234 industry funding had lower enrollment (<100), no blinding, and no randomization. (Table S2) . 241 242 Therapeutic focus 243

The plurality of obstetric trials focused on cesarean delivery (16.0% of all obstetric trials; Table  244 S3) with most of these funded by academic institutions (Table 1) . Infection was the most 245 frequent therapeutic focus among both industry (19.0%) and US government-funded trials 246 (30.2%). Obstetric trauma, thrombosis, and vomiting were the least frequent therapeutic foci 247 across all funders with the lowest enrollment ( Figure S1 , Table S3 ). 248 249

Obstetric trials compared to non-obstetric trials 251

Between 2007-2020, 47.5% of all obstetric trials reached completion, representing over 2.8 252 million participants (Table S4) . A total of 7.2% trials were discontinued early and 13.2% had 253 missing or unknown study status. In contrast, 51.3% of non-obstetric trials were completed, 8.8% 254 were discontinued early, and 10.2% had missing or unknown study status. Compared to non-255 obstetric trials, obstetric trials had a greater adjusted risk of early discontinuation (aHR 1.40; 256 95% confidence interval [CI] 1.21, 1.62; p<0.0001); Table 2 ; unadjusted analysis results in Table  257 S5 and when initiated, are at a greater risk of early discontinuation than non-obstetric trials. 291

Although obstetric trials report results at a similar rate to non-obstetric, only 15.3% of completed 292 obstetric trials report results. Our temporal analysis shows limited improvement in obstetric trial 293 quantity, almost entirely driven by academic institutions. 294

Our study adds to previous investigations of obstetric trials by suggesting the link 295 between funding, metrics of trial quality, trial completion and results reporting. We found among 296 obstetric trials, industry funds proportionally fewer large-scale trials, blinded trials, and 297 randomized trials. In contrast, US government-funded obstetric trials are the most likely to meet 298 CONSORT recommendations for trial quality 29 and to reach completion. When examining 299 results reporting by funder, even after controlling for other variables, we identified that 300 academically-funded trials are least likely to report results compared to other funders. 

Research Involving Women

The pregnant women as a drug orphan: a global survey of 425 registered clinical trials of pharmacological interventions in pregnancy

Characteristics and Publication Patterns of 428

Obstetric Studies Registered in ClinicalTrials.gov

Registered Obstetrics Trials

Clinical Trials Transformation Initiative

How to avoid common problems when using clinicaltrials.gov 436 in research: 10 issues to consider

The Quality of Registration of Clinical Trials. Scherer RW, ed. 438 19. ClinicalTrials.gov. ClinicalTrials.gov Protocol Registration Data Element Definitions for 446 Interventional and Observational Studies

FDAAA 801 and the Final Rule -ClinicalTrials

General Definition of Institution of Higher Education: 455 Institution of Higher Education

Kendall rank correlation and Mann-Kendall trend test. 459 btr0x2.rz.uni-bayreuth

The R Foundation. R: The R Project for Statistical Computing